Core Viewpoint - Federal Pharmaceutical (03933) has seen a significant stock increase of over 7%, currently trading at HKD 13.39, with a transaction volume of HKD 80.98 million, following the announcement of its innovative drug UBT251 receiving clinical trial approval for obesity-related moderate to severe obstructive sleep apnea (OSA) from the National Medical Products Administration of China [1] Group 1: Company Developments - Federal Pharmaceutical's wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has independently developed the innovative drug UBT251 injection, marking it as China's first chemical-synthesized GLP-1/GIP/GCG tri-target receptor agonist [1] - The company has established a significant position in the research field of this type of medication, enhancing its competitive edge in the pharmaceutical industry [1] Group 2: Market Analysis - UBS has released a report stating that Federal Pharmaceutical is a leading drug manufacturer in China, with an integrated business line that includes intermediate products, active pharmaceutical ingredients, and formulation products [1] - The report highlights that the market may be underestimating the sales potential of UBT251 and the broader innovative research pipeline of the company [1] - Last year, the company licensed the rights of UBT251 outside of China to Novo Nordisk (NVO.US), which included an upfront payment of USD 200 million, potential milestone payments of up to USD 1.8 billion, and tiered royalties on sales [1]
港股异动 | 联邦制药(03933)再涨超7% 瑞银认为市场低估UBT251销售潜力